Can digital tools make cancer genetic counseling more effective?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: EfFORT Trial Probands * Current MSK patient * Received post-test genetic counseling from MSK Clinical Genetics Service within the last 3 months (or within the last year for the de-identified non-randomized control probands) * 25 years of age or older * Self-reported "very well" comprehension of written and verbal English language or Spanish language * Has at least one ARR who meets criteria for study enrollment (see below) * First in the family to test positive for PV at MSK in any of the following cancer susceptibility genes, or an ARR of an MSK proband who converted to the proband role: APC I1307K, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDKN2A (P16), CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH6, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, SMAD4, BAP1, DICER1, FH, FLCN, HOXB13, KIT, MAX, MEN1, MET, MITF, PTCH1, RAD51B, RET, SDHB, SDHC, SDHD, STK11, SUFU, TMEM127, TSC1, TSC2, VHL Principal Investigator discretion will be used to determine whether specific variants within the above genes meet a clinical actionability threshold to warrant familial genetic testing. EfFORT Trial At-Risk Relatives (ARRs): * Biological first-, second-, or third- degree relative of enrolled MSK proband * 25 years of age or older * Resides within the United States * Self-reported medical insurance which can be in or out of network with MSK * Self-reported "very well" comprehension of written and verbal English language STRIVE Trial VUS Patients * Current MSK patient * Received post-test genetic counseling from MSK Clinical Genetics Service within the last 3 months * 25 years of age or older * Self-reported "very well" comprehension of written and verbal English language or Spanish language * Has a VUS identified in any of the following cancer predisposition genes: APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A (P16), CHEK2, CTNNA1, DICER1, ELOC, EPCAM, FH, FLCN, GREM1, HOXB13, KEAP1, MAX, MBD4, MEN1, MET, MITF, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NF1, NF2, NTHL1, PALB2, PMS2, POLD1, POLE, POT1, PTEN, RAD51B, RAD51C, RAD51D, RB1, RET, RNF43, RPS20, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, STK11, TERT, TMEM127, TP53, TSC1, TSC2, VHL STRIVE Trial PCP Providers: * Designated healthcare provider for an enrolled VUS patient * Resides within the United States Exclusion Criteria: EfFORT Trial Probands * Is unwilling or unable to provide informed consent * Is unwilling or unable to create a MyMSK patient portal account (see section 3.0 on MyMSK patient usage at MSK and CGS) * Does not have an email address * Has enrolled in the STRIVE trial EfFORT Trial At-Risk Relatives (ARRs): * Is unwilling or unable to provide informed consent * Is unwilling or unable to create a MyMSK patient portal account * Has previously undergone genetic testing for the familial PV * Does not have an email address * Has opted out of study contact STRIVE Trial VUS Patients * Is unwilling or unable to provide informed consent * Is unwilling or unable to create a MyMSK patient portal account (see section 3.0 on MyMSK patient usage at MSK and CGS) * Does not have an email address * Has enrolled in the EfFORT trial STRIVE Trial PCP Providers * Contact information not available